Although the therapeutic benefit of ePLND is controversial, with studies showing little improvement in the risk of BCR, cancer-specific mortality, or distant metastasis [6], this result could be due to the fact that most patients undergoing ePLND in the study had low risk cancer or no PLNM. This evidence concerns the gene BCR and cancer.